- Home
- CLW vs ATYR Comparison
CLW vs ATYR Comparison
Compare CLW & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLW
- ATYR
- Stock Information
- Founded
- CLW 2005
- ATYR 2005
- Country
- CLW United States
- ATYR United States
- Employees
- CLW N/A
- ATYR N/A
- Industry
- CLW Paper
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLW Basic Materials
- ATYR Health Care
- Exchange
- CLW Nasdaq
- ATYR Nasdaq
- Market Cap
- CLW 488.0M
- ATYR 451.3M
- IPO Year
- CLW N/A
- ATYR 2015
- Fundamental
- Price
- CLW $21.56
- ATYR $4.90
- Analyst Decision
- CLW Buy
- ATYR Strong Buy
- Analyst Count
- CLW 1
- ATYR 6
- Target Price
- CLW $36.00
- ATYR $20.20
- AVG Volume (30 Days)
- CLW 303.1K
- ATYR 6.1M
- Earning Date
- CLW 07-29-2025
- ATYR 08-07-2025
- Dividend Yield
- CLW N/A
- ATYR N/A
- EPS Growth
- CLW 345.10
- ATYR N/A
- EPS
- CLW 12.12
- ATYR N/A
- Revenue
- CLW $1,550,400,000.00
- ATYR N/A
- Revenue This Year
- CLW $14.34
- ATYR $551.06
- Revenue Next Year
- CLW $1.52
- ATYR $1,874.58
- P/E Ratio
- CLW $1.72
- ATYR N/A
- Revenue Growth
- CLW 34.73
- ATYR N/A
- 52 Week Low
- CLW $21.44
- ATYR $1.67
- 52 Week High
- CLW $35.38
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- CLW 31.67
- ATYR 44.49
- Support Level
- CLW $21.44
- ATYR $4.47
- Resistance Level
- CLW $22.84
- ATYR $5.75
- Average True Range (ATR)
- CLW 1.19
- ATYR 0.40
- MACD
- CLW -0.20
- ATYR -0.05
- Stochastic Oscillator
- CLW 1.40
- ATYR 24.93
About CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.